According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...
Extended pelvic lymph node dissection prolongs biochemical recurrence-free and metastasis-free survivals in localized prostate cancer.
Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC) No significant financial ...
A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...
Using real-world data, a team of U.S.-based investigators analyzed survival outcomes among an independent cohort of patients with metastatic urothelial cancer (UC) treated with immune checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results